Details for Patent: 7,598,257

Which drugs does patent 7,598,257 protect, and when does it expire?

Patent 7,598,257 protects OPZELURA, JAKAFI XR, and JAKAFI, and is included in three NDAs.

Protection for OPZELURA has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has one hundred and fifty-seven patent family members in thirty-five countries.

Summary for Patent: 7,598,257

Title:	Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as janus kinase inhibitors
Abstract:	The present invention provides heteroaryl substituted pyrrolo[2,3-b]pyridines and heteroaryl substituted pyrrolo[2,3-b]pyrimidines that modulate the activity of Janus kinases and are useful in the treatment of diseases related to activity of Janus kinases including, for example, immune-related diseases, skin disorders, myeloid proliferative disorders, cancer, and other diseases.
Inventor(s):	James D. Rodgers, Stacey Shepard
Assignee:	Incyte Corp , Incyte Holdings Corp
Application Number:	US11/637,545
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 7,598,257
Patent Claim Types: see list of patent claims	Use; Composition; Dosage form;

US Patent 7,598,257: Ruxolitinib Scope, Claims, Expiration, and Generic Risk

US Patent 7,598,257 is the principal composition-of-matter patent for ruxolitinib, the Janus kinase inhibitor marketed as Jakafi in the United States and Jakavi in many international markets. Its claims cover ruxolitinib itself, its R and S stereoisomers, pharmaceutically acceptable salts, pharmaceutical compositions, and treatment of myelofibrosis, polycythemia vera, and essential thrombocythemia.

The patent has unusually strong claim coverage because claims 1 to 3 reach the active molecule rather than only a formulation or clinical use. A valid, enforceable composition claim generally creates a substantial barrier to an ANDA applicant seeking approval for the same active ingredient.

What drug does US Patent 7,598,257 protect?

US 7,598,257 protects ruxolitinib, chemically identified as 3-cyclopentyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]propanenitrile.

The marketed pharmaceutical is generally ruxolitinib phosphate. Claim 1 covers the parent compound and pharmaceutically acceptable salts. The phosphate salt therefore falls within the salt coverage of the patent, assuming the salt is within the ordinary legal meaning of a pharmaceutically acceptable salt.

Item	Description
Active ingredient	Ruxolitinib
Primary marketed salt	Ruxolitinib phosphate
Drug class	JAK1/JAK2 inhibitor
US brand	Jakafi
International brand	Jakavi
US sponsor	Incyte Corporation
Main US indications	Myelofibrosis, polycythemia vera, acute graft-versus-host disease
Additional US product	Opzelura cream for topical dermatologic indications
Patent	US 7,598,257
Patent title	Substituted pyrazole compounds
Patent grant date	October 6, 2009
FDA approval of Jakafi	November 16, 2011

The patent claims supplied by the user are directed principally to ruxolitinib and three hematologic diseases. They do not expressly recite acute graft-versus-host disease, atopic dermatitis, vitiligo, or topical cream formulations.

What are the key claims in US 7,598,257?

The eight claims divide into four legal categories: chemical composition, stereochemistry, pharmaceutical composition, and method of treatment.

Claims 1 to 3: composition-of-matter protection

Claim 1 covers the racemic or non-stereospecified compound and its pharmaceutically acceptable salts.

Claims 2 and 3 separately cover the R and S enantiomers. Ruxolitinib is the R enantiomer. Separate stereochemical claims reduce the ability of an accused infringer to avoid the patent by arguing that the marketed drug is only one stereoisomer of a broader compound.

The relevant structure is:

• A cyclopentyl-substituted propanenitrile core.
• A pyrazole ring.
• A 7H-pyrrolo[2,3-d]pyrimidin-4-yl substituent.
• A stereogenic carbon bearing the cyclopentyl group and the nitrile-containing side chain.

These claims are technically narrow in chemical structure but broad in commercial effect. A generic manufacturer cannot ordinarily market the same active ingredient without addressing the composition claims, even if it uses a different synthetic route, excipient system, tablet coating, or manufacturing site.

Claim 4: pharmaceutical compositions

Claim 4 covers a composition containing any compound of claims 1 to 3, or a pharmaceutically acceptable salt, together with at least one pharmaceutically acceptable carrier.

This claim is broader than a specific tablet formula. It does not require a particular excipient, dosage strength, release profile, or route of administration. A conventional immediate-release tablet containing ruxolitinib phosphate and standard pharmaceutical excipients can fall within its scope.

Claim 5: oral and topical administration

Claim 5 narrows claim 4 to compositions suitable for oral or topical administration.

The oral language is commercially relevant to Jakafi tablets. The topical language is potentially relevant to ruxolitinib cream products, including Opzelura, although claim 5 does not by itself require a cream, emulsion, gel, specific concentration, or dermatologic indication.

A later patent may provide more specific protection for a topical formulation. Claim 5 remains relevant as a broader composition claim if its elements are met.

Claims 6 to 8: method-of-use claims

Claim	Disease
6	Myeloid metaplasia with myelofibrosis, also called MMM or primary myelofibrosis
7	Polycythemia vera
8	Essential thrombocythemia

Each claim requires administration of a therapeutically effective amount of the claimed compound or salt to a patient with the specified disease.

These claims are narrower than the compound claims because infringement depends on the treatment indication and the acts of administering or inducing administration. They are commercially important where the product label, prescribing information, promotional materials, or generic labeling includes one of the claimed uses.

How strong is the patent estate for ruxolitinib?

The core patent position is strong because US 7,598,257 contains composition-of-matter claims directed to the active pharmaceutical ingredient and its stereoisomers.

Protection layer	Covered by US 7,598,257?	Commercial significance
Ruxolitinib parent compound	Yes	Core barrier to generic entry
Ruxolitinib R enantiomer	Yes	Covers marketed active stereoisomer
Ruxolitinib S enantiomer	Yes	Prevents simple stereochemical design-around
Ruxolitinib phosphate	Yes, through salt language	Covers commercial drug substance
Oral composition	Yes	Relevant to Jakafi tablets
Topical composition	Potentially, through claim 5	Depends on composition and claim construction
Myelofibrosis treatment	Yes	Direct method-of-use protection
Polycythemia vera treatment	Yes	Direct method-of-use protection
Essential thrombocythemia treatment	Yes	Direct method-of-use protection
Acute graft-versus-host disease	Not expressly in supplied claims	Requires separate legal analysis
Atopic dermatitis or vitiligo	Not expressly in supplied claims	More relevant to later topical patents

The strongest claims are claims 1 to 3. A patent challenger that invalidates only a method claim would not remove the primary barrier to a conventional generic product. Conversely, a successful invalidity or noninfringement ruling against the composition claims could materially change the entry analysis.

When does US 7,598,257 expire?

Public drug-patent listings identify December 24, 2028 as the Orange Book expiration date associated with US 7,598,257. The date reflects the patent term as adjusted and listed for the product, rather than a simple calculation from the patent grant date. The patent granted in 2009, but the relevant term is based principally on the applicable filing and priority framework, including patent-term adjustment.

Milestone	Date
US patent grant	October 6, 2009
Jakafi FDA approval	November 16, 2011
Five-year NCE exclusivity	Ended in 2016
Listed patent expiration	December 24, 2028
Expected unrestricted generic opportunity	Generally after listed patent barriers expire, subject to litigation and other listed patents

Patent expiration does not automatically eliminate all market protection. A generic applicant may obtain approval before expiration if it prevails in litigation, obtains a favorable settlement date, or uses an approved labeling strategy that avoids protected indications.

What is the Orange Book status of US 7,598,257?

US 7,598,257 has been listed in the FDA Orange Book for ruxolitinib products. Orange Book listing matters because an ANDA applicant must address listed patents through one of four certifications:

1. Paragraph I: no patent information is listed.
2. Paragraph II: the patent has expired.
3. Paragraph III: the applicant will wait until patent expiration.
4. Paragraph IV: the patent is invalid, unenforceable, or will not be infringed.

For a core compound patent covering ruxolitinib, a Paragraph IV certification is the principal route to an early generic challenge. The NDA holder normally has 45 days after receiving a qualifying Paragraph IV notice to file an infringement action. A timely suit can trigger a 30-month stay of FDA approval under the Hatch-Waxman Act, subject to statutory exceptions and court decisions. FDA approval may occur before the listed expiration date if the litigation is resolved or the stay expires.

Which companies are challenging ruxolitinib patent protection?

Generic manufacturers have commercial incentives to challenge Jakafi patents because ruxolitinib is a small molecule with established demand in myelofibrosis and polycythemia vera. The relevant challenge mechanism is an ANDA Paragraph IV certification, not a biosimilar application.

Public patent-litigation and regulatory reporting has identified generic applicants, including companies such as Teva, Lupin, Apotex, and Zydus, in connection with ruxolitinib-related ANDA activity and patent disputes. The legal significance of each challenge depends on:

• The specific patents identified in the notice.
• Whether the applicant seeks all strengths and indications.
• Whether the applicant uses a carved-out label.
• Whether the litigation is dismissed, settled, or adjudicated.
• Whether the applicant receives 180-day first-filer eligibility.
• Whether later-listed patents remain enforceable.

A Paragraph IV filing is not an invalidity decision. It establishes a litigation pathway and can create a potential launch date, but it does not itself authorize commercial marketing.

What generic launch scenarios exist for ruxolitinib?

Scenario 1: Launch after December 2028

This is the lowest-risk scenario for the patent holder. A generic applicant waits for expiration of the core listed patents and launches after FDA approval. Commercial entry could still be delayed by manufacturing readiness, tentative approval, regulatory deficiencies, or separate listed patents.

Scenario 2: Settlement-based launch

The applicant and Incyte may agree to a licensed entry date before December 2028. Settlement terms can include:

• A fixed launch date.
• A royalty-bearing license.
• Restrictions on indication or dosage form.
• Covenants not to sue.
• Acceleration provisions if the patent is invalidated by another challenger.

The existence of a settlement does not establish that the patent is valid. It allocates litigation and market-entry risk.

Scenario 3: Successful Paragraph IV challenge

A generic applicant may launch before the listed expiration date if a court finds the relevant claims invalid or not infringed, or if Incyte fails to obtain an effective injunction. This scenario creates the largest revenue downside for Jakafi.

Scenario 4: Skinny-label entry

A generic may omit patented indications from its labeling under section viii of the Hatch-Waxman framework. This strategy can reduce method-of-use exposure but does not avoid a valid composition-of-matter patent covering the active ingredient.

For ruxolitinib, a skinny label is unlikely to overcome US 7,598,257 if the generic product itself falls within claims 1 to 3. It is more relevant to later use patents covering particular indications.

Does ruxolitinib have biosimilar risk?

No conventional biosimilar pathway applies to ruxolitinib because ruxolitinib is a chemically synthesized small-molecule drug, not a biological product licensed under the Public Health Service Act.

The principal competitive risk is generic substitution through the ANDA pathway. That distinction affects development cost, interchangeability, litigation timing, and market erosion:

Issue	Ruxolitinib
Product type	Small molecule
Regulatory pathway	ANDA
Biosimilar application	Not applicable
Main patent challenge	Paragraph IV
Automatic pharmacy substitution	Governed by state generic-substitution rules
Primary risk to Jakafi	Generic ruxolitinib tablets

Topical ruxolitinib products also face small-molecule generic risk, although topical formulation, delivery, concentration, and indication patents may create a more complex barrier than the oral tablet market.

What formulations are protected by the patent?

US 7,598,257 does not claim a detailed formulation recipe in the supplied claims. Claim 4 requires only the compound or salt and at least one pharmaceutically acceptable carrier. Claim 5 adds oral or topical suitability.

The patent therefore potentially reaches:

• Immediate-release tablets.
• Capsules.
• Oral powders or other oral dosage forms.
• Topical preparations.
• Formulations containing ruxolitinib phosphate.
• Formulations using conventional pharmaceutical excipients.

It does not expressly require:

• A specific dose such as 5 mg, 10 mg, 15 mg, or 20 mg.
• A specific excipient.
• A defined dissolution profile.
• A particular cream vehicle.
• A specific particle-size distribution.
• A particular manufacturing process.

Later patents may narrow these variables. A complete freedom-to-operate review for Jakafi or Opzelura must therefore examine continuation, divisional, formulation, salt, polymorph, process, and method-of-use families in addition to US 7,598,257.

How does US 7,598,257 compare with later ruxolitinib patents?

US 7,598,257 is the foundational compound patent. Later rights generally fall into narrower categories:

Patent category	Typical scope	Relative strength
Compound patent	Ruxolitinib structure and salts	Highest strategic value
Stereochemical patent	Specific enantiomer	Strong if separately valid
Formulation patent	Tablet, cream, vehicle, release profile	Narrower, product-specific
Method-of-use patent	Specific disease or patient population	Depends on label and conduct
Manufacturing patent	Route, intermediates, crystallization, purity	Can raise supply-chain barriers
Polymorph or salt patent	Solid form or salt characteristics	Depends on product form

The supplied claims do not establish the full later patent estate. They establish that the original patent had direct coverage of the drug substance and three early hematologic indications.

What licensing deals affect ruxolitinib?

Incyte retained US commercial rights to ruxolitinib and entered into a collaboration with Novartis for development and commercialization outside the United States. Novartis markets the product as Jakavi in numerous territories. The arrangement expanded international commercialization without transferring the core US commercial position.

The licensing structure is relevant to patent enforcement because:

• Incyte controls US Jakafi commercialization.
• Novartis has international commercial interests in licensed territories.
• Patent ownership, enforcement authority, and product revenue may differ by jurisdiction.
• A US generic settlement may not determine launch timing outside the United States.

What revenue exposure does the patent create?

Jakafi has been a major Incyte revenue product, with US sales concentrated in myelofibrosis and polycythemia vera. Ruxolitinib also supports international revenue through Novartis and topical revenue through Opzelura.

The commercial exposure is greater than the value of the original myelofibrosis label because:

• The drug has multiple hematologic indications.
• The product has long-term use in chronic disease.
• The active ingredient supports both oral and topical products.
• US reimbursement and specialty-pharmacy distribution can sustain high branded pricing before generic entry.
• A generic launch can affect net price, formulary position, and refill retention before full volume substitution occurs.

Generic erosion is usually fastest for standard oral tablets. Topical products may experience slower substitution if later patents, prescribing familiarity, or formulation differences limit automatic substitution.

Key Takeaways

• US 7,598,257 is the core ruxolitinib composition-of-matter patent.
• Claims 1 to 3 cover ruxolitinib, its R and S enantiomers, and pharmaceutically acceptable salts.
• The patent directly covers the active ingredient used in Jakafi, including the marketed phosphate salt.
• Claims 4 and 5 cover pharmaceutical compositions suitable for oral or topical administration.
• Claims 6 to 8 cover treatment of myelofibrosis, polycythemia vera, and essential thrombocythemia.
• The listed Orange Book expiration date is December 24, 2028.
• Ruxolitinib faces generic, not biosimilar, competition.
• Paragraph IV challenges are the primary route to an earlier US generic launch.
• Later formulation and method-of-use patents may affect particular products or indications, but they do not replace the importance of the core compound claims.
• A generic that uses the same ruxolitinib active ingredient cannot ordinarily avoid claims 1 to 3 merely by changing excipients or manufacturing methods.

FAQs

Is US 7,598,257 a composition-of-matter patent?

Yes. Claims 1 to 3 are composition claims directed to ruxolitinib and its stereoisomers. They are more commercially significant than the patent’s narrower composition and method-of-treatment claims.

Does ruxolitinib phosphate fall within US 7,598,257?

Yes, the claims expressly include pharmaceutically acceptable salts. Ruxolitinib phosphate is the principal marketed salt for oral Jakafi products.

Can a generic launch before December 2028?

Yes, but only through a successful patent challenge, a license or settlement, a noninfringing product strategy, or another legally effective route. A Paragraph IV certification alone does not authorize marketing.

Is Opzelura fully protected by US 7,598,257?

Not necessarily. Claim 5 covers compositions suitable for topical administration, but the supplied claims do not recite the specific cream formulation, concentration, dermatologic indication, or delivery system used by Opzelura. Those issues require analysis of later patents and claim scope.

Does a different manufacturing process avoid the patent?

Generally no. A different process does not avoid a valid product claim covering the same ruxolitinib molecule or salt. Process differences become more relevant only where the accused product does not fall within the product claims or where separate process patents are at issue.

References

1. United States Patent and Trademark Office. (2009). US Patent No. 7,598,257, Substituted pyrazole compounds. U.S. Department of Commerce.

2. U.S. Food and Drug Administration. (2011). Jakafi (ruxolitinib phosphate) prescribing information. FDA.

3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.

4. Incyte Corporation. (2024). Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. U.S. Securities and Exchange Commission.

5. Novartis Pharmaceuticals Corporation. (2024). Jakavi product information. Novartis.

6. Federal Food, Drug, and Cosmetic Act, 21 U.S.C. § 355(j).

7. Hatch-Waxman Amendments, Pub. L. No. 98-417, 98 Stat. 1585 (1984).

Drugs Protected by US Patent 7,598,257

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Incyte Corp	OPZELURA	ruxolitinib phosphate	CREAM;TOPICAL	215309-001	Sep 21, 2021		RX	Yes	Yes	7,598,257*PED				Y
Incyte Corp	JAKAFI XR	ruxolitinib phosphate	TABLET, EXTENDED RELEASE;ORAL	217180-001	May 1, 2026		RX	Yes	No	7,598,257*PED				Y
Incyte Corp	JAKAFI XR	ruxolitinib phosphate	TABLET, EXTENDED RELEASE;ORAL	217180-002	May 1, 2026		RX	Yes	No	7,598,257*PED				Y

International Family Members for US Patent 7,598,257

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
European Patent Office	1966202		C300574	Netherlands
European Patent Office	1966202		PA2013002	Lithuania
European Patent Office	1966202		CA 2013 00005	Denmark